Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

By Minghua Chen, V. Ona, Mingwei Li, R. Ferrante, K. Fink, Shan Zhu, J. Bian, Lei Guo, Laurie A. Farrell, S. Hersch and 4 more. Nature Medicine, 2000

1,118 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/506337624df3096b1303e4f9dfec0c8bb56358cd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Linda R. Watkins
2. S. Maier
3. E. Milligan
4. C. Zuccato
5. E. Cattaneo
6. M. Valenza
7. S. Przedborski
8. P. Pacher

In Molecular Biology

1. G. van Loo
2. M. Lamkanfi
3. S. Maier
4. E. Milligan
5. L. Liaudet
6. S. Przedborski
7. Linda R. Watkins
8. M. Valenza

Citations in the corpus

• The physiology and pathophysiology of nitric oxide in the brain. (2005, result): “This observation is in accordance with the increased iNOS expression seen in glial, neuronal and vascular cells from brains of HD patients and HD mouse models (Chen et al., 2000).”
• Nitric oxide and peroxynitrite in health and disease. (2007, background): “Accordingly, increased iNOS expression was observed in neuronal, glial, and vascular cells from brains of HD patients and mouse models of disease (206, 491).”
• Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice (2003, positive): “Neuroprotective therapies targeted at specific molecular mechanisms have the potential to dramatically delay the onset and slow the progression of disease in transgenic mouse models of HD (Chen et al., 2000; Ferrante et al., 2000, 2002a,b; Andreassen et al., 2001a,b; Dedeoglu et al., 2002, 2003; Kar”
• Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease (2002, background): “, 1998) and in a mouse model of Huntington’s disease (Chen et al., 2000), appears to do so by abating iNOS expression and activity.”
• Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation (2005, background): “Minocycline has been reported to inhibit ICE mRNA in brain (Chen et al., 2000; Yrjanheikki et al., 1998) and MMP-9 protein in cultured T lymphocytes (Brundula et al.”
• Contributions of Inflammatory Processes to the Development of the Early Stages of Diabetic Retinopathy (2007, background): “It has been speculated that its neuroprotective action is mediated by the inhibition of activation of caspase-1 and caspase3, inhibition of generation of IL-1β, and iNOS [170, 171].”
• Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia1 (2001, background): “Considering the neuroprotection achieved with minocycline in animal models of stroke (24, 25) and Huntington’s disease (26), our cell culture findings suggest that minocycline may represent a potential therapeutic agent for treatment of brain diseases which involve excitotoxicity.”
• Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications (2013, background): “, 2008) which potentially reduces inflammatory cytokines by inhibiting caspase synthesis (Chen et al., 2000), MK2/3 (MAP kinase associated protein-kinase 2 and 3) inhibitors (Duman et al.”
• Inhibition of Microglial Activation Attenuates the Development but Not Existing Hypersensitivity in a Rat Model of Neuropathy (2003, background): “It is an effective neuroprotective agent in experimental brain ischemia (Yrjanheikki et al., 1998), in the R6/2 mouse model of Huntington’s disease (Chen et al., 2000), in traumatic brain injury (Sanchez Mejia et al., 2001), and in the 6-hydroxydopamine and…”
• Molecular mechanisms and potential therapeutical targets in Huntington's disease. (2010, background): “Minocycline, a second-generation tetracycline, was found to inhibit caspase 1 and 3 in R6/2 mice, improving the disease phenotype (111, 254, 418, 622).”
• Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia (2001, background): “minocycline inhibits caspase expression and delays mortality (Chen et al., 2000).”
• Inflammasomes in neuroinflammatory and neurodegenerative diseases (2019, background): “…(Wellington et al, 1998) and in vivo (Ona et al, 1999), potentially contributing to the neurodegeneration seen in HD. Similarly, treatment with the tetracycline derivative minocycline was shown to delay disease progression by inhibition of caspase-1 and caspase-3 expression (Chen et al, 2000).”